Abstract:
Background-Percutaneous mitral valve repair (MVR) with the MitraClip TM device has emerged as an alternative to surgery for treating severe mitral regurgitation (MR). However, its effects on left ventricular (LV) loading conditions and contractility have not been investigated yet.
Methods and Results-Pressure-volume (PV) loops were recorded throughout the MitraClip TM procedure using conductance catheter in 33 patients (mean age, 78±10 years) with functional (45%), degenerative (48%), or mixed (6%) MR. Percutaneous MVR increased end-systolic wall stress (WS ES ) (from (median (IQR)) 184 (140-200) to 209 (176-232) mmHg, P=0.001) and decreased end-diastolic wall stress (WS ED ) (from 48 to 34 mmHg, P=0.005), while end-systolic pressure-volume relationship (ESPVR) was not significantly affected.
Conversely, CI increased (from 2.6 (2.2-3.0) to 3.2 (2.6-3.8) L/min/m 2 , P<0.001) and mean PCWP decreased (from 15 (12) (13) (14) (15) (16) (17) (18) (19) (20) to 12 (10-13) mmHg, P<0.001). While changes in WS ES ( WS ES ) were not correlated with CI, WS ED correlated significantly with mPCWP (r=0.63, P<0.001). Total mechanical energy assessed by the pressure-volume area (PVA) remained unchanged resulting in a more favourable forward output (CI) to mechanical energy (PVA) ratio after MVR. On follow-up (153±94 days), NYHA functional class was reduced from 2.9±0.6 to 1.9±0.5 (P<0.001) at 3 months and echocardiographic follow-up documented a stepwise reduction in end-diastolic volume (from 147 to 127 (82-202) mL, P=0.036). 
Conclusions-Percutaneous

Introduction
Recently, a novel percutaneous method for mitral valve repair (MVR) has been developed. 1 Conceptually, this technique is based on the surgical method developed by Alfieri which consists of edge-to-edge approximation of the middle scallops of the mitral valve leaflets by percutaneous delivery of a mitral clip, thereby creating a double-orifice mitral valve. 2 Based on promising initial clinical experiences with percutaneous edge-to-edge MVR, [3] [4] [5] [6] [7] the MitraClip TM device has been implanted in over 6000 patients worldwide. However, data on the hemodynamic consequences of percutaneous MVR are scarce, 8, 9 and its effect on left ventricular (LV) preload, afterload and contractility, the main determinants of LV pump performance, are yet to be investigated.
Simultaneous in vivo pressure-volume (PV) measurements with a conductance catheter (CC) placed in the left ventricle allow real-time assessment of the LV PV relationship. 10 In fact, percutaneous MVR provides a unique pathophysiological model for assessing the immediate hemodynamic effects of MR reduction on LV performance, eliminating any confounding factors from cardiopulmonary bypass or chordal ablation. Preliminary experiences suggest that despite an initial slight decrease in LV ejection fraction, percutaneous edge-to-edge MVR did not negatively affect cardiac output, 8, 9 and, so far, no reports of acute low-output states after MVR have been published yet, even in patients with markedly compromised LV function. 9 However, the mechanisms by which percutaneous edge-to-edge MVR may influence LV pump performance and affect LV preload, afterload and contractility are still to be determined.
Thus, the purpose of this study was to investigate acute changes in LV PV relationships during percutaneous edge-to-edge MVR with the MitraClip TM device using a CC, and to relate these findings to acute hemodynamic changes and mid-term clinical outcomes.
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Methods
Patient Population and Study Design
We included consecutive patients undergoing percutaneous MVR using the MitraClip TM system at the University Hospital Zurich, Switzerland. Patients were selected for the procedure if they had moderate-to-severe (3+) or severe (4+) mitral regurgitation (MR), 11 and was approved by the local institutional review board.
Mitral Valve Repair Procedure
Percutaneous MVR with the MitraClip TM device (Abbott Vascular Structural Heart, Menlo Park, CA) was performed according to standard technique described elsewhere 9 with echocardiographic (3D transesophageal echocardiography) and fluoroscopic guidance. General anesthesia was established with a continuous infusion of intravenous propofol and remifentanil and patients were ventilated routinely with an inspiratory oxygen fraction (FiO 2 ) of 60 to 80%, which was maintained over the entire duration of the procedure. Acute procedural success (APS) was defined as successful MitraClip implantation with MR reduction to grade 2+ or less by endocarditis, mitral valve orifice area 2.0 cm 2 , extensively prolapse of flail leaf afl le lets ts s (pr pr prol ol olap ap apse se s width >25 mm, flail gap >20 mm) or any interventional or surgical r procedure within 30 days of h he e in in inde de dex x pr pr proc oced d dur ur ure. e All patients gave written in n nf fo for rm med consent t to o o be e i i inc nc nclu l ded in a prospective M Mit tr traC a lip regi ist str r ry (M Mi Mitr r raS aS aSwi wi wiss ss ss r reg eg gis is str try) y). . 
echocardiography.
Instrumentation
Simultaneous LV PV measurements were performed with a CC (CD Leycom, Zoetermeer, The Netherlands). This catheter is a pigtail-shaped central-lumen 7-french flexible catheter that is placed in the left ventricle via a 0.025-inch J-tipped guide-wire. It contains a solid-state pressure sensor and 12 electrodes at regular intervals and is connected to a pressure-volume signal processor (Inca, CD Leycom). The conductance method calculates continuous LV volume tracings by measuring parallel electrical conductance between a number of electrodes situated at regular intervals along the catheter, and has been successfully validated against cine-CT and electro-conductive balloons in animals. 14, 15 The correct position of the conductance catheter was 
where WS(t) is LV wall stress, P(t) LV pressure and V(t) LV volume at a given timepoint throughout the cardiac cycle. This formula assumes that wall stress is fairly uniform throughout the ventricular wall and is relatively independent of the geometry of the LV. 22 LV wall volume (V wall ) was calculated according to the cube function formula which approximates the shape of the LV as a prolate ellipsoid of regular configuration and a ratio of long-to short-axis lengths of 2:1: 23
where IVST d is the diastolic thickness of the inter-ventricular septum, PWT d the diastolic posterior wall thickness and EDD the end-diastolic diameter measured on M-mode echocardiography.
CO and cardiac index (CI) were calculated using the Fick method. 24 Systemic (SVR) and pulmonary vascular resistance (PVR) were calculated as the ratio between the pressure drop along the vascular bed and the cardiac output and converted in metric units (dynes·sec·cm -5 ).
Clinical and Echocardiographic Follow-up
Clinical follow-up was obtained from follow-up visits, in-hospital records and/or direct interview of the patient or his/her general practitioner. Clinical endpoints included death, recurrent hospitalization for congestive heart failure (CHF), mitral valve surgery, and New York Heart Association (NYHA) functional class.
LV volumes at follow-up were assessed from 2-dimensional transthoracic echocardiography using the area-length method, 25 and systolic pulmonary pressure was
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Statistical Analysis
Statistical analysis was performed using the SPSS software package 26 A p value <0.05 was considered statistically significant for all tests.
Results
Patient Population
Of 37 consecutive patients undergoing percutaneous MVR, hemodynamic data and PV loops were obtained in 33 patients. 
Results
Procedural Outcome
MitraClip implantation was successful in 31/33 patients (APS rate 94%) with an average of 1.9
implanted clips per patient (1 clip in 7 patients, 2 clips in 21 patients, 3 clips in 4 patients, and 4 clips in 1 patient). The procedure failed in two patients due to excessive posterior anular calcification with poor echocardiographic image quality (n=1) or partial clip detachment (n=1).
Post-interventional complication rates were low, and there was no in-hospital death. Two of the patients required vasopressor therapy over 1 -3 days after the procedure, but none had intraaortic balloon counterpulsation.
Hemodynamic Data
All hemodynamic variables were obtained under general anesthesia before and immediately after the MitraClip procedure, and are summarized in (Figure 2) . Figure 3 shows individual examples for PV loops before and after percutaneous MVR.
LV myocardial energetics
Percutaneous MVR decreased eSW ( 4) . Changes in echocardiographic parameters (including volumes and EF) were similar among DMR versus FMR patients.
Comparison between degenerative and functional MR
Discussion
The present study addressed the immediate effects of percutaneous MVR with the MitraClip TM on left ventricular performance (including left ventricular contractility, afterload and preload) as 
Changes in LV Loading Conditions
Surgical observations have raised the concern, that removing the low-impedance regurgitant flow into the left atrium may abruptly impair left ventricular performance resulting in an acute postoperative low-output state. [27] [28] [29] [30] However, these observations are confounded by factors such as changes in LV geometry induced by chordal ablation and extracorporeal circulation, both of which may underlie deterioration of LV contractility. 27 We observed a significant 21% increase in LV afterload (estimated based on WS ES ) after percutaneous MVR which likely contributes to the acute decline in LV EF observed after MVR.
The reduction in the regurgitant fraction decreases systolic offloading by occluding the lowimpedance left atrial pathway. However, in our study population, a large increase in systolic load did not predict low cardiac output after MVR (Figure 2, panel A) . Conversely, a significant 17% reduction in LV preload could be observed. This effect of diastolic LV unloading was associated with a reduction in pulmonary pressures (Figure 2, panel B) . Therefore, the beneficial effect of diastolic LV unloading appears to outweigh the potentially negative afterload increase. An acute
Surgical observations have raised the concern, that removing the low-impedance regurgitant flow n nto to o t t the he he l l lef ef eft t t at at a rium um um m may abruptly impair left ven ntr tr tric icu ular performa anc nc n e re re esu su sulting in an acute post st top o erative lo low-w-w-ou utp tput ut ut s s sta ta tate te te. 27 27 27 27 decrease in LV afterload in heart failure patients by intra-aortic balloon pumping has been shown to induce acute leftward shifts of the LV PV plane along the patient's end-systolic elastance curve, resulting in acute increase in stroke volume and concomitant decrease in preload. 31 Conversely, it can be expected that decreasing the LV offloading effects of MR will acutely increase the afterload along the patients end-systolic elastance.
Contrary to the general notion, afterload tends to be high in chronic MR due to progressive ventricular enlargement particularly in the decompensated stage. 20, 32 Thus, an uncontrolled increase in LV afterload, also termed "afterload excess", is an important concern after MR correction as it may lead to further deterioration of LV function. Several studies have documented a significant increase in systolic LV load after successful mitral valve surgery in patients with chronic decompensated MR but not in the chronic compensated stage. 19, 33 It may well be that some of our patients were in the chronic decompensated stage which would explain the increase in afterload. However, an important difference to previously mentioned studies is that we assessed cardiac loading conditions immediately (i.e. minutes) after correction of the MR whereas others used echocardiographic assessment several days after surgery allowing for early LV remodeling to take place.
Compared to patients with DMR, the reduction in LV preload (measured by EDP and WS ED ) and increase in CI were significantly lower in FMR patients. These differences in ventricular unloading after MVR in DMR versus FMR patients can be explained by fundamentally different pathophysiologic mechanisms underlying the etiology of heart failure in these two subgroups. In DMR, the effect of MR on the LV is predominantly volume overload which can be effectively reversed by reducing or abolishing MR. However, in FMR the pathophysiology of heart failure is more complex and involves reduced contractility due to documented a significant increase in systolic LV load after succe n ssful mitral val lv v ve s s sur rge ge gery ry ry i i in n n patients with chronic decompensated MR but not in the chronic compensated stage. t 19, 33 It may percutaneous MVR is more difficult to predict. Nonetheless, while afterload was higher in FMR patients at baseline, there was no excess afterload increase after MVR compared to DMR (table   3) . However, it should be noted that the sample size for both subgroups was small, which precludes any firm clinical conclusion.
Effects of Percutaneous MVR on Left Ventricular Contractility
We could demonstrate that despite a significant acute decline in EF, percutaneous MVR did not significantly affect LV contractility measured by ESPVR estimating the endsystolic elastance, a load-independent index of LV contractility. The SCI also did not change significantly, however its application as load-independent index of contractile state during a MVR procedure is questionable because it will already increase by decreasing protosystolic regurgitation. Also PRSW as index of contractile state is not applicable for MVR because eSW decreases due the decrease in mitral regurgitation.
Previous observations have also shown substantial disparity between ejection fraction and end-systolic indices of LV contractility in the presence of MR. 34 Interestingly, neither loadindependent parameters of LV contractility nor EF demonstrated a clinically relevant correlation to cardiac output indicating that the improvement in hemodynamic status is achieved through the reduction of regurgitant flow rather than any substantial changes in LV contractility.
Deterioration of LV contractility occurs late into the natural history of chronic mitral regurgitation and marks the transition into the chronic decompensated stage. 32, 35 These patients 34 34 34 Int nt nter er eres es esti ti ting ng ngly ly, , ne ne neit it ithe he her r load-changes in load-independent contractility parameters appeared even more favourable in our group of patients with FMR (with even a 7% increase in SCI and ESPVR) compared to DMR (table 3) . Thus, percutaneous MVR using the MitraClip TM device appears to spare LV contractility and therefore may still be considered as valuable treatment option of chronic FMR in patients with poor ventricular contractility. On the other hand, percutaneous MVR does not eliminate MR in all patients, which may contribute to poor outcomes in a subset of patients.
Effect of Percutaneous MVR on LV Energetics
Percutaneous MVR resulted in an energy transfer from eSW to PE. This shift represents a loss of efficiency in the transfer of energy from the PVA to external mechanical work (eSW), and has been described earlier as a physiological response to an abrupt increase in afterload in experimental animal models. 18 However, net total mechanical energy measured by the PVA (the main determinant of myocardial oxygen consumption) remained unchanged after MVR. Thus the ratio of forward cardiac output to PVA (multiplied by heart rate) increased significantly by a median of 23%. This indicates, that percutaneous MVR may improve forward cardiac output by approximately ¼ for a given unit of total mechanical energy (PVA) and hence, myocardial oxygen consumption. This may be a particularly attractive feature in patients with ischemic cardiomyopathy, in which myocardial oxygen delivery may be compromised and therefore an increased oxygen demand could lead to significant myocardial ischemia.
Relationship of CC Measurements and Hemodynamic Changes to Clinical and
Echocardiographic outcomes
Although LV volumes do not decrease immediately after MVR, there is a downward trend in the first months after the procedure with a decrease in EDV indicating a favourable reverse LV remodeling. This reverse remodeling may be a result of improved hemodynamic conditions from been described earlier as a physiological response to an abrupt increase in afterlo load ad ad i in n experimental animal models. 18 There is evidence from prior work that the salutary hemodynamic changes elicited by percutaneous MVR translate into improved clinical outcomes. 9 Nonetheless, despite the short follow-up, event rates (death, readmission for CHF) were considerable given the substantial comorbid status of our patients. However, the limited number of subjects and the lack of a control group precludes any firm conclusion about the relationship of the observed hemodynamic changes with any potential clinical benefit. A recent non-randomized study documented superiority of percutaneous MVR compared to medical treatment in patients with predominantly functional MR 37 indicating that despite high event rates, percutaneous MVR still offers a clinical benefit over medical treatment. Nonetheless, larger prospective randomized trials are eagerly awaited to confirm this hypothesis.
Limitations
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limited and therefore are unlikely to play a significant confounding role.
We did not measure end-systolic elastance (I.e. the slope of the ESPVR, a loadindependent index of LV contractility) as this generally requires an intervention such as inflation of an occlusive balloon in the inferior vena cava.
Finally, by the very nature of the procedure, all measurements were acquired during general anesthesia, which is known to underestimate loading conditions compared to the conscious non-sedated state. 9 Therefore, absolute values for preload, afterload and contractility parameters may be different in the conscious state. Additionally, hyperoxygenation resulted in higher mixed venous oxygen saturations and, consequently, higher values for CO and CI calculated by the Fick method than would be expected for this population. Finally, assumptions on resting oxygen consumption do not necessarily apply to the anesthetized patient and are a further limitation of the Fick principle. However, since pre-and post-procedural measurements were obtained under the same conditions, the relative changes of the latter parameters are expected to represent true changes.
Clinical implications
Despite significant morbidity and mortality, many patients with severe MR are denied surgery due to a high surgical risk and poor outcomes 38 . Percutaneous MVR with the MitraClip TM system represents a novel and promising treatment alternative in nonsurgical candidates. The 1 1) ) <0.001 1 S SVR VR dy dyn* n*s* s*cm cm - 5 9 995 95(7 (796 96 1 126 261) 1) 9 995 95 ( (63 633 3 10 1092 92) ) 9 95 5 ( ( 20 209 9 12 12) ) 0 0 03 03 
